Form 4: Director Johannes Schikan Sells Pharvaris Shares

Pharvaris N.V. director Johannes Schikan sold 32,900 shares of common stock via a pre-arranged 10b5-1 trading plan.

Summary

• Director Johannes Schikan sold a total of 32,900 shares of Pharvaris N.V. (PHVS) common stock.
• The sales occurred on April 29 and April 30, 2026.
• Transactions were executed under a pre-established Rule 10b5-1 trading plan.
• Following these transactions, the director retains beneficial ownership of 355,167 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales were executed through a pre-planned 10b5-1 program, which is a standard and transparent practice for corporate insiders.

Positives

• The sales were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell shares without triggering concerns regarding non-public information.

Negatives

• The transaction represents a reduction in the director's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived negatively by the market, potentially impacting short-term investor sentiment.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider sales executed via 10b5-1 plans are common in the biotechnology sector, often used by executives and directors for liquidity and diversification rather than reflecting a change in outlook on the company's clinical or commercial prospects.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for corporate insiders to manage equity holdings while maintaining compliance with SEC regulations.
• The volume of shares sold is relatively small compared to the director's remaining holdings, which is consistent with typical portfolio rebalancing.

Stakeholder Impact

• Minimal impact expected as the sales were pre-planned and represent a small portion of the director's total holdings.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Pharvaris, PHVS, Insider Trading, Form 4, Johannes Schikan, Biotech